| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.73 [0.67, 0.80] | | < 1 | | 58% | 21 studies (21/-) | 100.0 % | low | low | high | crucial | - |
| deaths (OS) (extension) | 0.65 [0.57, 0.73] | | < 1 | | 66% | 8 studies (8/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS | 0.70 [0.58, 0.84] | | < 1 | | 36% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| MFS (extension) | 0.76 [0.64, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.53 [0.44, 0.64] | | < 1 | | 80% | 7 studies (7/-) | 100.0 % | low | not evaluable | high | important | - |
| progression or deaths (PFS) | 0.61 [0.52, 0.70] | | < 1 | | 79% | 15 studies (15/-) | 100.0 % | low | low | high | important | - |
| RFS (extension) | 0.67 [0.56, 0.80] | | < 1 | | 65% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| RFS/DFS | 0.56 [0.44, 0.71] | | < 1 | | 67% | 6 studies (6/-) | 100.0 % | low | serious | high | important | - |
| DCR | 1.09 [0.89, 1.33] | | > 1 | | 0% | 3 studies (3/-) | 79.2 % | low | not evaluable | high | non important | - |
| DMFS | 0.60 [0.49, 0.73] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| DOR | 0.59 [0.38, 0.92] | | < 1 | | 45% | 2 studies (2/-) | 99.0 % | low | not evaluable | high | non important | - |
| DOR (extension) | 3.45 [1.46, 8.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.57 [1.76, 3.76] | | > 1 | | 90% | 19 studies (19/-) | 100.0 % | low | low | high | non important | - |
| objective responses (ORR) (extension) | 5.31 [3.93, 7.17] | | > 1 | | 55% | 5 studies (5/-) | 100.0 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.07 [1.19, 3.60] | | < 1 | | 71% | 11 studies (11/-) | 0.5 % | low | low | high | non important | - |
| AE (grade 3-4) | 1.10 [0.56, 2.13] | | < 1 | | 97% | 11 studies (11/-) | 39.3 % | low | low | high | non important | - |
| AE leading to death (grade 5) | 1.50 [0.91, 2.46] | | < 1 | | 0% | 9 studies (9/-) | 5.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.81 [0.77, 10.28] | | < 1 | | 95% | 8 studies (8/-) | 5.9 % | low | serious | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.55 [0.30, 21.54] | | < 1 | | 96% | 5 studies (5/-) | 19.6 % | low | serious | high | non important | - |
| SAE (any grade) | 2.14 [0.98, 4.66] | | < 1 | | 89% | 5 studies (5/-) | 2.8 % | low | not evaluable | high | non important | - |
| SAE (grade 3-4) | 2.63 [0.83, 8.34] | | < 1 | | 89% | 4 studies (4/-) | 5.1 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.97 [0.97, 3.98] | | < 1 | | 88% | 7 studies (7/-) | 3.1 % | low | serious | high | non important | - |
| STRAE (grade 3-4) | 4.03 [1.07, 15.21] | | < 1 | | 67% | 6 studies (6/-) | 2.0 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 1.87 [1.22, 2.86] | | < 1 | | 93% | 22 studies (22/-) | 0.2 % | low | low | high | non important | - |
| TRAE (grade 3-4) | 2.19 [1.29, 3.72] | | < 1 | | 96% | 22 studies (22/-) | 0.2 % | low | critical | high | non important | - |
| TRAE leading to death (grade 5) | 1.74 [0.87, 3.49] | | < 1 | | 0% | 17 studies (17/-) | 5.9 % | low | low | high | non important | - |
| TRAE leading to discontinuation (any grade) | 2.59 [1.17, 5.72] | | < 1 | | 96% | 15 studies (15/-) | 0.9 % | low | low | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.30 [0.95, 5.56] | | < 1 | | 94% | 13 studies (13/-) | 3.3 % | low | low | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.64 [0.23, 1.82] | | < 1 | | 0% | 11 studies (11/-) | 79.8 % | low | low | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.59 [0.20, 12.46] | | < 1 | | 0% | 3 studies (3/-) | 33.0 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.58 [0.79, 3.16] | | < 1 | | 0% | 14 studies (14/-) | 9.7 % | low | low | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.24, 3.81] | | < 1 | | 0% | 8 studies (8/-) | 52.8 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.45 [0.15, 1.30] | | < 1 | | 4% | 8 studies (8/-) | 92.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.32 [0.68, 2.56] | | < 1 | | 0% | 15 studies (15/-) | 21.0 % | low | low | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.69 [0.32, 1.49] | | < 1 | | 0% | 11 studies (11/-) | 82.6 % | low | low | high | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 2.58 [0.36, 18.33] | | < 1 | | 0% | 3 studies (3/-) | 17.3 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.78 [0.09, 6.72] | | < 1 | | 0% | 3 studies (3/-) | 58.9 % | low | not evaluable | high | non important | - |
| Chills TRAE (grade 3-4) | 0.84 [0.17, 4.19] | | < 1 | | 0% | 6 studies (6/-) | 58.3 % | low | not evaluable | high | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.90 [0.91, 3.97] | | < 1 | | 78% | 18 studies (18/-) | 4.3 % | low | low | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.20, 4.56] | | < 1 | | 0% | 6 studies (6/-) | 52.2 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.97 [0.28, 3.31] | | < 1 | | 0% | 9 studies (9/-) | 52.1 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.28 [0.49, 3.33] | | < 1 | | 0% | 13 studies (13/-) | 30.5 % | low | critical | high | non important | - |
| Diabetes TRAE (grade 3-4) | 2.03 [0.51, 8.05] | | < 1 | | 0% | 6 studies (6/-) | 15.7 % | low | serious | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.31 [0.77, 2.23] | | < 1 | | 73% | 21 studies (21/-) | 15.6 % | low | low | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.95 [0.10, 9.23] | | < 1 | | 0% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 1.32 [0.68, 2.53] | | < 1 | | 0% | 12 studies (12/-) | 20.6 % | low | low | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.95 [0.10, 9.23] | | < 1 | | 0% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.95 [0.10, 9.23] | | < 1 | | 0% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.76 [0.65, 4.80] | | < 1 | | 0% | 10 studies (10/-) | 13.4 % | low | low | high | non important | - |
| Ear and labyrinth disorders TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 3.45 [1.24, 9.62] | | < 1 | | 62% | 10 studies (10/-) | 0.9 % | low | low | high | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 1.13 [0.23, 5.64] | | < 1 | | 0% | 5 studies (5/-) | 44.1 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 1.01 [0.50, 2.04] | | < 1 | | 42% | 14 studies (14/-) | 48.5 % | low | low | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 2.81 [0.41, 19.25] | | < 1 | | 0% | 3 studies (3/-) | 14.8 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 3.03 [1.01, 9.08] | | < 1 | | 90% | 11 studies (11/-) | 2.4 % | low | low | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 2.81 [0.41, 19.25] | | < 1 | | 0% | 3 studies (3/-) | 14.8 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.84 [0.32, 2.19] | | < 1 | | 0% | 11 studies (11/-) | 64.1 % | low | low | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.47 [1.87, 6.43] | | < 1 | | 0% | 18 studies (18/-) | 0.0 % | low | low | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 2.83 [0.51, 15.67] | | < 1 | | 86% | 9 studies (9/-) | 11.8 % | low | serious | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.68 [0.38, 18.88] | | < 1 | | 0% | 3 studies (3/-) | 16.2 % | low | not evaluable | high | non important | - |
| Hypertension TRAE (grade 3-4) | 0.95 [0.10, 9.23] | | < 1 | | 0% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.88 [0.81, 4.36] | | < 1 | | 0% | 16 studies (16/-) | 7.1 % | low | critical | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.96 [0.52, 1.76] | | < 1 | | 24% | 18 studies (18/-) | 55.8 % | low | low | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.43, 2.25] | | < 1 | | 0% | 19 studies (19/-) | 51.2 % | low | low | high | non important | - |
| Increase AST TRAE (grade 3-4) | 2.22 [0.86, 5.74] | | < 1 | | 68% | 16 studies (16/-) | 5.0 % | low | low | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.78 [1.13, 6.89] | | < 1 | | 76% | 16 studies (16/-) | 1.3 % | low | low | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.82 [1.19, 2.78] | | < 1 | | 42% | 9 studies (9/-) | 0.3 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.45 [0.27, 7.62] | | < 1 | | 0% | 5 studies (5/-) | 33.2 % | low | serious | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.19 [0.05, 0.74] | | < 1 | | 0% | 6 studies (6/-) | 99.2 % | low | serious | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.48 [0.95, 2.30] | | < 1 | | 0% | 15 studies (15/-) | 4.3 % | low | low | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.44 [0.23, 8.93] | | < 1 | | 0% | 3 studies (3/-) | 35.0 % | low | not evaluable | high | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.95 [0.11, 8.51] | | < 1 | | 25% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.15 [0.48, 2.76] | | < 1 | | 0% | 13 studies (13/-) | 37.4 % | low | critical | high | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.97 [0.07, 58.99] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.95 [0.19, 4.71] | | < 1 | | 0% | 6 studies (6/-) | 52.7 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.84 [0.40, 1.76] | | < 1 | | 0% | 15 studies (15/-) | 67.6 % | low | low | high | non important | - |
| Nephritis TRAE (grade 3-4) | 1.03 [0.15, 6.90] | | < 1 | | 0% | 3 studies (3/-) | 48.7 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 3.11 [0.83, 11.67] | | < 1 | | 4% | 5 studies (5/-) | 4.7 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.23 [0.07, 0.79] | | < 1 | | 0% | 8 studies (8/-) | 99.1 % | some concern | serious | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.95 [0.10, 9.23] | | < 1 | | 0% | 3 studies (3/-) | 51.7 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.56 [0.46, 5.29] | | < 1 | | 0% | 8 studies (8/-) | 23.7 % | low | not evaluable | high | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.50 [0.04, 5.71] | | < 1 | | 14% | 2 studies (2/-) | 71.0 % | low | not evaluable | high | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.77 [0.20, 2.91] | | < 1 | | 0% | 8 studies (8/-) | 65.2 % | some concern | serious | moderate | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.92 [0.24, 3.56] | | < 1 | | 0% | 6 studies (6/-) | 54.7 % | low | not evaluable | high | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.13 [0.97, 4.66] | | < 1 | | 0% | 14 studies (14/-) | 2.9 % | low | low | high | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.78 [0.18, 3.32] | | < 1 | | 0% | 7 studies (7/-) | 63.1 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.53 [0.78, 3.02] | | < 1 | | 0% | 20 studies (20/-) | 11.0 % | low | critical | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.38 [0.60, 3.16] | | < 1 | | 0% | 12 studies (12/-) | 22.5 % | low | low | high | non important | - |
| Rash TRAE (grade 3-4) | 1.33 [0.82, 2.17] | | < 1 | | 13% | 18 studies (18/-) | 12.4 % | low | low | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.99 [0.08, 12.98] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | low | not evaluable | high | non important | - |
